focus -WSS

focus

author：focus 2025-09-28 00:52:29 - browse：46721

Bob Kocher, a partner at venture capital firm Venrock, speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Health tech investor Bob Kocher has seen some bad AI-related startup pitches in his time. The worst typically involve AI chatbots masquerading as romantic partners to improve people’s mental health.

“They pitch it to me as a mental health improvement model,” Kocher, a partner at venture capital firm Venrock, said. “If you’re sad, anxious, or depressed, why bother with people?”

Kocher, who is also a doctor and helped write the Affordable Care Act as an Obama administration health official, shared his thoughts on the biggest questions facing digital health at STAT’s Breakthrough Summit on Thursday. Besides sharing a peek inside his generative AI pitch-filled inbox, Kocher talked about cybersecurity vulnerabilities in health systems and venture capitalists buying hospitals.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Readout LOUD podcast: Live from the 2023 STAT Summit

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

STAT Summit: The economic case for universal basic health care

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Roivant's CEO is a star, but biotech's black hole persists

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

CZI to create biohub to build anti

What does generative AI mean for health care? We asked experts

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Walensky prepares to leave CDC — and Congress — behind

ADCs take center stage as promising cancer treatments

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: mifepristone case, GLP

DIEP, the 'gold standard' of breast reconstruction, is under threat

How AI can help patients find reliable information about doctors

hotspot

STAT Summit: Ending the crisis of Black deaths in the U.S.

Health tech investors get more selective as pandemic boom fades

ADCs take center stage as promising cancer treatments

Patient advocates debate FDA's accelerated approval process

Roche acquires Telavant from Roivant, adding experimental IBD treatment

The problems with dementia villages

leisure time

explore

focus

leisure time